For Physicians

Text

Scientific Publications & Presentations

Custirsen Scientific Publications & Presentations

Clinical Publications

Prostate Cancer

  • Pain Palliation as an Oncology Label Indication: Lessons Learned in Custirsen Phase 3 Development. Beer TM, Hotte SJ, DeBono J, et al. American Society of Clinical Oncology Genitourinary Cancers Symposium 2014: Abstract 222. View Poster
  • Design of the AFFINITY study: A randomized phase III study of a novel clusterin inhibitor, custirsen, plus cabazitaxel/prednisone (CbzP) versus CbzP alone as second-line chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). Trial in Progress: Beer TM, Blumenstein BA, Fizazi K, et al. J Clin Oncol. ASCO Annual Meeting Proceedings 2013;31(15) suppl, 2013: TPS5103. View Abstract
  • A randomized phase 3 study comparing first-line docetaxel/prednisone (DP) to DP plus custirsen in men with metastatic castration-resistant prostate cancer (mCRPC). Chi KN, Higano C, Reeves J, et al. European Society of Medical Oncology Congress 2014: Abstract 7550. View Abstract
  • Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. Chi KN, Hotte SJ, Yu EY, et al. J Clin Oncol. 2010;28(27):4247-54. View Abstract
  • Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Saad F, Hotte S, North S, et al. Clin Cancer Res. 2011;17:5765-73. View Abstract
  • A Phase II neoadjuvant study of OGX-011, a 2’-methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to prostatectomy. Chi KN, Goldenberg L, Kollmannsberger C et al. American Society of Clinical Oncology Genitourinary Cancers Symposium 2008: Abstract 167. View Poster
  • Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen. Blumenstein B, Saad F, Hotte S, et al. Cancer Med. 2013;2(4):468-77. View Publication
  • Potential use of custirsen to treat prostate cancer. Higano CS. Onco Targets Ther. 2013;6:785-97. View Abstract
  • Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer. Zielinski R, Chi KN. Future Oncol. 2012;8(10):1239-51. View Abstract

Non-small Cell Lung Cancer (NSCLC)

  • Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. Laskin JJ, Nicholas G, Lee C, et al. J Thorac Oncol. 2012;7(3):579-86. View Abstract

General Publications

  • Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Zoubeidi A, Chi K, Gleave M. Clin Cancer Res. 2010;16(4):1088-93. View Abstract
  • A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Chi KN, Siu LL, Hirte H, et al. Clin Cancer Res. 2008;14(3):833-39. View Abstract
  • Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. Chi KN, Zoubeidi A, Gleave M. Expert Opin Investig Drugs. 2008;17(12):1955-62. View Abstract

Preclinical Publications

  • Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. Sowery RD, Beraldi E, So AI, et al. BJU Int. 2008;102(3):389-97. View Abstract
  • Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. July LV, Beraldi E, So A, et al. Mol Cancer Ther. 2004;3(3):223-32. View Abstract

Apatorsen Scientific Publications & Presentations

Clinical Publications

Bladder Cancer

  • The Borealis-2 clinical trial: A randomized phase II study of OGX-427 plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer. Trial in Progress: Rosenberg JE, Hahn NM, Regan MM, et al. J Clin Oncol. ASCO Annual Meeting Proceedings 2013;31(15) suppl, 2013: TPS4588^. View Abstract
  • A phase I trial of intravesical antisense oligonucleotide targeting heat shock protein 27 (OGX-427) for the treatment of non-muscle-invasive bladder cancer. So A, Black P, Chi KN, et al. J Clin Oncol. Genitourinary Cancers Symposium; 30(5) suppl, 2012: 286. View Poster

Prostate Cancer

  • The Pacific trial: A randomized phase II study of OGX-427 in men with metastatic castration-resistant prostate cancer (mCRPC) and PSA progression while receiving abiraterone acetate (AA). Trial in Progress: Chi KN, Sweeney C, Jacobs C, et al. J Clin Oncol. ASCO Annual Meeting Proceedings 2013;31(15) suppl, 2013: TPS5105. View Abstract
  • A randomized phase II study of OGX-427 plus prednisone (P) vs. P alone in patients (PTS) with metastatic castration resistant prostate cancer (CRPC). Chi KN, Yu Y, Ellard S, et al. European Society of Medical Oncology Congress 2012: Abstract 2795. View Poster
  • The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer. Ischia J1, Saad F, Gleave M. Curr Opin Urol. 2013 May;23(3):194-200. doi: 10.1097/MOU.0b013e32835e9f1a. View Abstract

Pancreatic Cancer

  • Double-blind randomized phase II trial of carboplatin and pemetrexed with or without OGX-427 in patients with previously untreated stage IV non-squamous non-small-cell lung cancer (NSCLC): The Spruce Clinical Trial. Trial in Progress: Spigel DR, Burris HA, Greco FA et al. J Clin Oncol. ASCO Annual Meeting Proceedings 2013;31(15) suppl, 2013: TPS8120. View Abstract

General Publications

  • Phase I trial of OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): Final results. Hotte SJ, Yu EY, Hirte HW, et al. J Clin Oncol. ASCO Annual Meeting Proceedings 2010;28(15) suppl, 2010: 3077. View Poster
  • Small heat shock proteins in cancer therapy and prognosis. Zoubeidi A, Gleave M. Int J Biochem Cell Biol. 2012;44(10):1646-56. View Abstract

Preclinical Publications

  • Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Shiota M, Bishop JL, Nip KM, et al. Cancer Res. 2013;73(10):3109-19. View Abstract
  • Cotargeting stress-activated Hsp27 and autophagy as a combinatorial strategy to amplify endoplasmic reticular stress in prostate cancer. Kumano M, Furukawa J, Shiota M, et al. Mol Cancer Ther. 2012;11(8):1661-71. View Abstract
  • OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Baylot V, Andrieu C, Katsogiannou M, et al. Cell Death Dis. 2011;2(10):e221. View Abstract
  • Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer. Matsui Y, Hadaschik BA, Fazli L, et al. Mol Cancer Ther. 2009;8(8):2402-11. View Abstract
  • Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer. Hadaschik BA, Jackson J, Fazli L, et al. BJU Int. 2008;102(5):610-16. View Abstract
  • Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Kamada M, So A, Muramaki M, et al. Mol Cancer Ther. 2007;6(1):299-308. View Abstract
  • Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Rocchi P, Beraldi E, Ettinger S, et al. Cancer Res. 2005;65(23):11083-93. View Abstract

Click here to automatically receive emails when new scientific publications and presentations are added to this site.

External Link Pop Up Window

You are now exiting the OncoGenex Web site and entering a third party Web site.

OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.

Stay on OncoGenex Continue